NasdaqCM - Nasdaq Real Time Price USD
BioXcel Therapeutics, Inc. (BTAI)
1.5600
-0.2050
(-11.61%)
At close: June 13 at 4:00:00 PM EDT
1.5300
-0.03
(-1.92%)
After hours: June 13 at 7:31:43 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | 2 |
| Avg. Estimate | -1.13 | -0.64 | -6.19 | -6.95 |
| Low Estimate | -1.13 | -0.64 | -9.17 | -11.87 |
| High Estimate | -1.13 | -0.64 | -3.21 | -2.02 |
| Year Ago EPS | -3.36 | -5.12 | -22.55 | -6.19 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | 2 |
| Avg. Estimate | 200k | 300k | 1.68M | 4.93M |
| Low Estimate | 200k | 300k | 1M | 3.9M |
| High Estimate | 200k | 300k | 2.35M | 5.97M |
| Year Ago Sales | 1.1M | 214k | 2.27M | 1.68M |
| Sales Growth (year/est) | -81.88% | 40.19% | -26.02% | 194.27% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -10.99 | -7.68 | -5.14 | -3.04 |
| EPS Actual | -3.36 | -5.12 | -3.56 | -1.5 |
| Difference | 7.63 | 2.56 | 1.58 | 1.54 |
| Surprise % | 69.42% | 33.33% | 30.73% | 50.66% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -1.13 | -0.64 | -6.19 | -6.95 |
| 7 Days Ago | -2.16 | -1.84 | -9.17 | -9.94 |
| 30 Days Ago | -2.16 | -1.84 | -23.27 | -15.88 |
| 60 Days Ago | -2.16 | -1.84 | -23.27 | -15.88 |
| 90 Days Ago | -2.16 | -1.84 | -13.49 | -8 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | -- | 1 |
| Up Last 30 Days | 1 | 1 | -- | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| BTAI | 66.37% | 87.50% | 72.55% | -12.20% |
| S&P 500 | 13.13% | 2.43% | 7.54% | 14.06% |
Upgrades & Downgrades
| Initiated | Rodman & Renshaw: Buy | 3/19/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 1/30/2025 |
| Downgrade | B of A Securities: Buy to Underperform | 1/7/2025 |
| Maintains | Canaccord Genuity: Buy to Buy | 1/6/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 10/21/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/6/2024 |
Related Tickers
XFOR X4 Pharmaceuticals, Inc.
2.8200
-7.54%
FGEN FibroGen, Inc.
0.2639
-14.46%
AXSM Axsome Therapeutics, Inc.
104.10
-2.02%
ABP Abpro Corporation
0.2150
-11.85%
MRSN Mersana Therapeutics, Inc.
0.3672
+1.13%
PALI Palisade Bio, Inc.
0.6401
-7.23%
PHIO Phio Pharmaceuticals Corp.
2.2700
-8.10%
IVVD Invivyd, Inc.
0.7920
-6.47%
ONCO Onconetix, Inc.
4.7300
-24.90%
PCSA Processa Pharmaceuticals, Inc.
0.2585
-24.92%